Substrate-Guided Design of a Potent and Selective Kallikrein-Related Peptidase Inhibitor for Kallikrein 4

Chemistry and Biology

Volumn 16, Issue 6, 2009, Pages 633-643

  Swedberg, Joakim E ^a   Nigon, Laura V ^a   Reid, Janet C ^a   de Veer, Simon J ^a   Walpole, Carina M ^a   Stephens, Carson R ^a   Walsh, Terry P ^a   Takayama, Thomas K ^b   Hooper, John D ^a   Clements, Judith A ^a   Buckle, Ashley M ^c   Harris, Jonathan M ^a  

^a QUEENSLAND UNIVERSITY OF TECHNOLOGY   (Australia)

^b UNIVERSITY OF WASHINGTON   (United States)

^c Victorian Bioinformatics Consortium   (Australia)

Author keywords

CHEMBIO; PROTEINS

Indexed keywords

KALLIKREIN; KALLIKREIN 4; PEPTIDE; PEPTIDE LIBRARY; PROTEINASE ACTIVATED RECEPTOR; SERINE PROTEINASE INHIBITOR;

ANIMAL; ARTICLE; CHEMISTRY; COMPUTER SIMULATION; DRUG ANTAGONISM; DRUG DESIGN; ENZYME ACTIVE SITE; ENZYME SPECIFICITY; HUMAN; KINETICS; MALE; METABOLISM; MOUSE; PROSTATE TUMOR; PROTEIN CONFORMATION; TUMOR CELL LINE;

ANIMALS; CATALYTIC DOMAIN; CELL LINE, TUMOR; COMPUTER SIMULATION; DRUG DESIGN; HUMANS; KALLIKREINS; KINETICS; MALE; MICE; PEPTIDE LIBRARY; PEPTIDES; PROSTATIC NEOPLASMS; PROTEIN CONFORMATION; RECEPTORS, PROTEINASE-ACTIVATED; SERINE PROTEINASE INHIBITORS; SUBSTRATE SPECIFICITY;

HELIANTHUS;

EID: 67649547851     PISSN: 10745521     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.chembiol.2009.05.008     Document Type: Article

References (42)

1. Abbenante J., Leung D., Bond T., and Fairlie D.P. An efficient Fmoc strategy for the rapid synthesis of peptide para-nitroanilides. Lett. Pept. Sci. 7 (2000) 347-351
2. Arlt M., Kopitz C., Pennington C., Watson K.L.M., Krell H.-W., Bode W., Gansbacher B., Khokha R., Edwards D.R., and Kruger A. Increase in gelatinase-specificity of matrix metalloproteinase inhibitors correlates with antimetastatic efficacy in a T-cell lymphoma model. Cancer Res. 62 (2002) 5543-5550
3. Beaufort N., Debela M., Creutzburg S., Kellermann J., Bode W., Schmitt M., Pidard D., and Magdolen V. Interplay of human tissue kallikrein 4 (hK4) with the plasminogen activation system: hK4 regulates the structure and functions of the urokinase-type plasminogen activator receptor (uPAR). Biol. Chem. 387 (2006) 217-222
4. Beynon R.J., and Bond J.S. Proteolytic Enzymes: A Practical Approach (1989), Oxford University Press, New York
5. Brunger A.T., Adams P.D., Clore G.M., DeLano W.L., Gros P., Grosse-Kunstleve R.W., Jiang J.S., Kuszewski J., Nilges M., Pannu N.S., et al. Crystallography & NMR system: A new software suite for macromolecular structure determination. Acta Crystallogr. D Biol. Crystallogr. 54 (1998) 905-921
6. Chambers A.F., and Matrisian L.M. Changing views of the role of matrix metalloproteinases in metastasis. J. Natl. Cancer Inst. 89 (1997) 1260-1270
7. Coughlin S.R. How the protease thrombin talks to cells. Proc. Natl. Acad. Sci. USA 96 (1999) 11023-11027
8. Coughlin S.R. Protease-activated receptors in hemostasis, thrombosis and vascular biology. J. Thromb. Haemost. 3 (2005) 1800-1814
9. Daly N.L., Chen Y.-K., Foley F.M., Bansal P.S., Bharathi R., Clark R.J., Sommerhoff C.P., and Craik D.J. The absolute structural requirement for a proline in the P3′-position of Bowman-Birk protease inhibitors is surmounted in the minimized SFTI-1 scaffold. J. Biol. Chem. 281 (2006) 23668-23675
10. Darmoul D., Marie J.C., Devaud H., Gratio V., and Laburthe M. Initiation of human colon cancer cell proliferation by trypsin acting at protease-activated receptor-2. Br. J. Cancer 85 (2001) 772-779
11. Davis I.W., Murray L.W., Richardson J.S., and Richardson D.C. MOLPROBITY: structure validation and all-atom contact analysis for nucleic acids and their complexes. Nucleic Acids Res. 32 (2004) W615-W619
12. Debela M., Magdolen V., Schechter N., Valachova M., Lottspeich F., Craik C.S., Choe Y., Bode W., and Goettig P. Specificity profiling of seven human tissue kallikreins reveals individual subsite preferences. J. Biol. Chem. 281 (2006) 25678-25688
13. Descours A., Moehle K., Renard A., and Robinson J.A. A new family of beta-hairpin mimetics based on a trypsin inhibitor from sunflower seeds. ChemBioChem 3 (2002) 318-323
14. Emsley P., and Cowtan K. Coot: model-building tools for molecular graphics. Acta Crystallogr. D Biol. Crystallogr. 60 (2004) 2126-2132
15. Even-Ram S., Uziely B., Cohen P., Grisaru-Granovsky S., Maoz M., Ginzburg Y., Reich R., Vlodavsky I., and Bar-Shavit R. Thrombin receptor overexpression in malignant and physiological invasion processes. Nat. Med. 4 (1998) 909-914
16. Gao J., Collard R.L., Bui L., Herington A.C., Nicol D.L., and Clements J.A. Kallikrein 4 is a potential mediator of cellular interactions between cancer cells and osteoblasts in metastatic prostate cancer. Prostate 67 (2007) 348-360
17. Henrikson K.P., Salazar S.L., Fenton J.W., and Pentecost B.T. Role of thrombin receptor in breast cancer invasiveness. Br. J. Cancer 79 (1999) 401-406
18. Hidalgo M., and Eckhardt S.G. Development of matrix metalloproteinase inhibitors in cancer therapy. J. Natl. Cancer Inst. 93 (2001) 178-193
19. Hilpert K., Hansen G., Wessner H., Volkmer-Engert R., and Hohne W. Complete substitutional analysis of a sunflower trypsin inhibitor with different serine proteases. J. Biochem. 138 (2005) 383-390
20. Hollenberg M.D. Proteinase-mediated signaling: Proteinase-activated receptors (PARs) and much more. Life Sci. 74 (2003) 237-246
21. Huck C.W., Pezzei V., Schmitz T., Bonn G.K., and Bernkop-Schnürch A. Oral peptide delivery: Are there remarkable effects on drugs through sulfhydryl conjugation?. J. Drug Target. 14 (2006) 117-125
22. Jemal A., Siegel R., Ward E., Hao Y., Xu J., Murray T., and Thun M.J. Cancer Statistics, 2008. CA Cancer J. Clin. 58 (2008) 71-96
23. Korsinczky M.L., Schirra H.J., Rosengren K.J., West J., Condie B.A., Otvos L., Anderson M.A., and Craik D.J. Solution structures by 1H NMR of the novel cyclic trypsin inhibitor SFTI-1 from sunflower seeds and an acyclic permutant. J. Mol. Biol. 311 (2001) 579-591
24. Kruger A., Soeltl R., Sopov I., Kopitz C., Arlt M., Magdolen V., Harbeck N., Gansbacher B., and Schmitt M. Hydroxamate-type matrix metalloproteinase inhibitor Batimastat promotes liver metastasis. Cancer Res. 61 (2001) 1272-1275
25. Li P., Jiang S., Lee S.L., Lin C.Y., Johnson M.D., Dickson R.B., Michejda C.J., and Roller P.P. Design and synthesis of novel and potent inhibitors of the type II transmembrane serine protease, matriptase, based upon the sunflower trypsin inhibitor-1. J. Med. Chem. 50 (2007) 5976-5983
26. Long Y.Q., Lee S.L., Lin C.Y., Enyedy I.J., Wang S., Li P., Dickson R.B., and Roller P.P. Synthesis and evaluation of the sunflower derived trypsin inhibitor as a potent inhibitor of the type II transmembrane serine protease, matriptase. Bioorg. Med. Chem. Lett. 11 (2001) 2515-2519
27. Luckett S., Garcia R.S., Barker J.J., Konarev A.V., Shewry P.R., Clarke A.R., and Brady R.L. High-resolution structure of a potent, cyclic proteinase inhibitor from sunflower seeds. J. Mol. Biol. 290 (1999) 525-533
28. Malone S., Perry G., Segal R., Dahrouge S., and Crook J. Long-term side-effects of intermittent androgen suppression therapy in prostate cancer: results of a phase II study. BJU Int. 96 (2005) 514-520
29. Matsumura M., Bhatt A.S., Andress D., Clegg N., Takayama T.K., Craik C.S., and Nelson P.S. Substrates of the prostate-specific serine protease prostase/KLK4 defined by positional-scanning peptide libraries. Prostate 62 (2005) 1-13
30. Mize G.J., Wang W., and Takayama T.K. Prostate-specific kallikrein-2 and -4 enhance the proliferation of DU145 prostate cancer cells through protease-activated receptors-1 and -2. Mol. Cancer Res. 6 (2008) 1043-1051
31. Nierodzik M.L., Chen K., Takeshita K., Li J.J., Huang Y.Q., Feng X.S., D'Andrea M.R., Andrade-Gordon P., and Karpatkin S. Protease-activated receptor 1 (PAR-1) is required and rate-limiting for thrombin-enhanced experimental pulmonary metastasis. Blood 92 (1998) 3694-3700
32. Obiezu C.V., Michael I.P., Levesque M.A., and Diamandis E.P. Human kallikrein 4: enzymatic activity, inhibition, and degradation of extracellular matrix proteins. Biol. Chem. 387 (2006) 749-759
33. Overall C.M., and Lopez-Otin C. Strategies for MMP inhibition in cancer: innovations for the post-trial era. Nat. Rev. Cancer 2 (2002) 657-672
34. Potterton L., McNicholas S., Krissinel E., Gruber J., Cowtan K., Emsley P., Murshudov G.N., Cohen S., Perrakis A., and Noble M. Developments in the CCP4 molecular-graphics project. Acta Crystallogr. D Biol. Crystallogr. 60 (2004) 2288-2294
35. Ramsay A.J., Dong Y., Hunt M.L., Linn M., Samaratunga H., Clements J.A., and Hooper J.D. Kallikrein-related peptidase 4 (KLK4) initiates intracellular signaling via protease-activated receptors (PARs): KLK4 and PAR-2 are co-expressed during prostate cancer progression. J. Biol. Chem. 283 (2008) 12293-12304
36. Ramsay A.J., Reid J.C., Adams M.N., Samaratunga H., Dong Y., Clements J.A., and Hooper J.D. Prostatic trypsin-like kallikrein-related peptidases (KLKs) and other prostate-expressed tryptic proteinases as regulators of signalling via proteinase-activated receptors (PARs). Biol. Chem. 389 (2008) 653-668
37. Snyder G.H., Cennerazzo M.J., Karalis A.J., and Locey D. Electrostatic influence of local cysteine environments on disulfide exchange kinetics. Biochemistry 20 (1981) 6509-6519
38. Takayama T.K., Fujikawa K., and Davie E.W. Characterization of the precursor of prostate-specific antigen. J. Biol. Chem. 272 (1997) 21582-21588
39. Takayama T.K., McMullen B.A., Nelson P.S., Matsumura M., and Fujikawa K. Characterization of hK4 (prostase), a prostate-specific serine protease: activation of the precursor of prostate specific antigen (pro-PSA) and single-chain urokinase-type plasminogen activator and degradation of prostatic acid phosphatase. Biochemistry 40 (2001) 15341-15348
40. Veveris-Lowe T.L., Lawrence M.G., Collard R.L., Bui L., Herington A.C., Nicol D.L., and Clements J.A. Kallikrein 4 (hK4) and prostate-specific antigen (PSA) are associated with the loss of E-cadherin and an epithelial-mesenchymal transition (EMT)-like effect in prostate cancer cells. Endocr. Relat. Cancer 12 (2005) 631-643
41. Xi Z., Klokk T.I., Korkmaz K., Kurys P., Elbi C., Risberg B., Danielsen H., Loda M., and Saatcioglu F. Kallikrein 4 is a predominantly nuclear protein and is overexpressed in prostate cancer. Cancer Res. 64 (2004) 2365-2370
42. Zablotna E., Jaskiewicz A., Legowska A., Miecznikowska H., Lesner A., and Rolka K. Design of serine proteinase inhibitors by combinatorial chemistry using trypsin inhibitor SFTI-1 as a starting structure. J. Pept. Sci. 13 (2007) 749-755